EODData

MEMBERSHIP REGISTER LOG IN

NASDAQ, LNTH: Lantheus Holdings

06 Nov 25 17:20
LAST:

53.69

CHANGE:
 3.54		OPEN:
61.10		HIGH:
62.00		ASK:
17.95		VOLUME:
2.69M
CHG(%):
6.19		PREV:
57.23		LOW:
53.36		BID:
16.78		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
06 Nov 2561.1062.0053.3653.692.69M
05 Nov 2556.8758.0756.1357.232.06M
04 Nov 2557.0058.2356.6957.711.12M
03 Nov 2557.6958.4056.0256.821.42M
31 Oct 2555.0157.8854.7657.691.25M
30 Oct 2555.9156.9155.2055.49724.8K
29 Oct 2557.2057.5755.7755.881.25M
28 Oct 2558.0658.1356.2757.331.08M
27 Oct 2556.0658.3056.0658.131.26M
24 Oct 2556.7256.9156.0056.06651.6K

COMPANY PROFILE

Name:Lantheus Holdings
About:Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. It also provides Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; PYLARIFY AI, an medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer; and flurpiridaz used to assess blood flow to the heart. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy to patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent for Tau tangles in Alzheimer's disease; LNTH-2401, a novel radiodiagnostic targeting the gastrin-releasing peptide receptor; LNTH-2402; LNTH-2403; LNTH-2404; and LNTH-1363S, an fibroblast activation protein, alpha, copper-64 labeled PET imaging agent. It has collaboration agreements with GE Healthcare; POINT; Regeneron; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.
Sector:Healthcare
Address:201 Burlington Road, Bedford, MA, United States, 01730
Website:https://www.lantheus.com
CUSIP:516544103
CIK:0001521036
ISIN:US5165441032
FIGI:BBG006Q52RD0
LEI:5299005HUB5IOJGO7S39

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:15.34 
Forward P/E:8.32 
PEG Ratio:0.53 
Price to Sales:2.58 
Price to Book:3.36 
Profit Margin:0.18 
Operating Margin:0.23 
Return on Assets:0.13 
Return on Equity:0.25 
EPS Ratio:3.76 
Revenue:1.521B 
EBITDA:537.94M 
Shares:67.99M 
Market Cap:3.651B 

TECHNICAL INDICATORS

MA5:56.635.5%
MA10:56.605.4%
MA20:56.284.8%
MA50:54.170.9%
MA100:62.1815.8%
MA200:76.4742.4%
RSI14:44.19
WPR14:-100.00 
MTM14:-2.91
ROC14:-0.05 
ATR:2.24 
Week High:62.0015.5%
Week Low:53.360.6%
Month High:62.0015.5%
Month Low:49.6742.4%
Year High:111.29107.3%
Year Low:47.2513.6%
Volatility:15.57